Materias dentro de su búsqueda.
Mostrando 21,501 - 21,520 Resultados de 21,534 Para Buscar '"títere"', tiempo de consulta: 0.23s Limitar resultados
  1. 21501
    “…Most likely, resistance of LDV replication to antiviral immune responses is related to the unique structure of its envelope proteins and the production of large quantities of viral antigens. High titers of anti-LDV antibodies are generated in infected mice but they neutralize LDV infectivity only very inefficiently and, even though the antiviral antibodies are mainly of the IgG2a and IgG2b isotypes, they do not mediate complement lyses of virions [31]. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Lactate dehydrogenase-elevating virus: an ideal persistent virus?
  2. 21502
    “…We observed higher increase of binding titers following heterologous boost with INO-4802 (3.6 – 4.4 log2-fold change) than homologous boost with pWT (2.0 – 2.4 log2 fold change) (Figure 4). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    579. Design and Immunogenicity of a Pan-SARS-CoV-2 Synthetic DNA Vaccine
  3. 21503
    “…PATIENT AND METHODS In this observational prospective study, anti-SARS-CoV-2 spike IgG antibody titers and circulating neutralizing antibodies were measured at 1 and 3 months after the 1 (st) dose of vaccination. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Timing and Immune Status after Cellular Therapies Predict Response to COVID-19 Vaccines
  4. 21504
    “…Conclusion Our study, to the best of our knowledge, is the first study comparing pre and post vaccination IgG titers against the SARS-CoV-2 S protein. Majority of patients with MM and solid organ malignancies, including those receiving active treatment, responded adequately to immunization. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Evaluation of Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunizations in Patients with B-Cell Malignancies
  5. 21505
    “…Moreover, the level of the T-cell response (log transformed) correlated linearly with (log transformed) anti-spike IgG titer (adjusted r=0.26 and p =0.026 according to Pearson correlation, Figure 1). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Cellular Immune Responses to BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia
  6. 21506
    “…Primary endpoints were the geometric mean titer (GMT) of neutralizing antibodies against wild-type SARS-CoV-2 and 7-day solicited adverse reactions. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial
  7. 21507
    “…HI outcomes included RSV-A and RSV-B neutralizing antibody (NAb) geometric mean titers (GMTs) and RSVPreF3-specific immunoglobulin G (IgG) antibody geometric mean concentrations (GMCs). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    96. A Candidate Respiratory Syncytial Virus (RSV) Prefusion F Protein Investigational Vaccine (RSVPreF3 OA) Is Immunogenic when Administered in Adults ≥ 60 Years of Age: Results at 6 Months after Vaccination
  8. 21508
    por Noguchi, Hideyo
    Publicado 1920
    “…Polyvalent immune sera, one specific for icteroides, and the other for icterohæmorrhagiæ, showed a high titer of neutralizing power for the cultures of the homologous groups. …”
    Enlace del recurso
    Enlace del recurso
    Texto
    ETIOLOGY OF YELLOW FEVER : X. COMPARATIVE IMMUNOLOGICAL STUDIES ON LEPTOSPIRA ICTEROIDES AND LEPTOSPIRA ICTEROHÆMOORRHAGIÆ.
  9. 21509
    “…V114 and PCV13 were immunogenic in all subgroups based on OPA geometric mean titers (GMTs) at 30 days post-vaccination for the 13 shared STs (Figure); in addition, V114 induced a robust immune response to the 2 unique STs (22F, 33F) in all subgroups. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1050. Phase 3 Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by 23valent Pneumococcal Polysaccharide Vaccine 6 Months Later in At-risk Adults Aged 18–49 Years (PNEU-DAY): A Subgroup Analysis by Baseline Risk Factors
  10. 21510
    “…ADAMTS13 activity level was t <5% (normal >/= 70%), with positive ADAMTS13 inhibitor screen and titer of 1.5 (normal <0.4), consistent with relapsed aTTP. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Relapsed Refractory Acquired Thrombotic Thrombocytopenic Purpura (aTTP) Following COVID-19 Vaccination
  11. 21511
    “…The mRNA vaccines BNT162b2 and mRNA-1273 have robust safety and efficacy with 95-97% prevention of severe COVID-19 disease and development of protective antibody titers in 92 - 100% of healthy individuals. By contrast, some pts with hematological malignancy fail to produce anti-spike antibodies (Ab) despite full courses of vaccination. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Determinants of COVID-19 Vaccine Response in Patients with Lymphoma on B Cell Directed Therapy
  12. 21512
    “…S-protein pseudotyped lentiviral transduction of hACE2.293T was confirmed with increase in BL from baseline across diminishing viral titer (n=3; Fig. 2). Control 293T cells without hACE2 expression were not transduced, confirming specificity of viral binding and entry dependent on hACE2 (n=3; Fig. 2). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    CAR-NK Cells Targeting Sars-Cov-2 Glycosites As COVID-19 Treatment
  13. 21513
    “…The primary objective is safety and secondary objectives include assessment of titers and durability of S-specific IgG (bAbs) and nAb responses of GRT-R910 boost vaccinations as well as T cell responses to S and non-S epitopes. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2346. Preliminary results of durable immune response induced by a self-amplifying mRNA (samRNA) SARS-CoV-2 vaccine candidate, GRT-R910, in adults previously vaccinated with mRNA or AZD1222 primary series
  14. 21514
    “…RESULTS: We observed a strong nuclear staining pattern (titer >1280) with the characteristic even-sized coarse speckles and no staining of nucleoli in sera from three patients. …”
    Enlace del recurso
    Enlace del recurso
    Texto
    Heterogeneous nuclear ribonucleoproteins C1/C2 identified as autoantigens by biochemical and mass spectrometric methods
  15. 21515
    “…Likewise, it was not possible to relate serological titers to the severity of the disease, as this was not one of the selection criteria.In 40/70 donors (57.2%) IgM remained above 1.2 AU / mL after the 21st day of symptom onset. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Antibody Response Against Sars-Cov-2 in Convalescent Plasma Donors: Preliminary Results from a Single Center in Midwest Brazil
  16. 21516
    “…In Phase 1, 78% (14/18) and 84% (16/19) of subjects generated neutralizing antibody responses with geometric mean titers (GMTs) of 17.4 (95%CI 8.3, 36.5) and 62.3 (95% CI 36.4, 106.7) in the 1.0 and 2.0 groups, respectively (Figure 1). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    571. Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster
  17. 21517
    “…The anti-COVID-19 IgG titers on semiquantitative test (n=47, all after mRNA-based vaccines) were also lower in pts with active disease compared with those in remission (P=.065) or under WW (P=.028), and in those with prior anti-B-cell antibody (P=.0095). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Factors Associated with Seroconversion after COVID-19 Vaccination in Patients with Hematologic Malignancies
  18. 21518
    “…The duration of a humoral response against COVID-19, protective antibody titer and connection with clinical outcomes in CML pts need further evaluation in parallel with a common population. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Humoral Immunity and Adverse Events after Vaccination Against COVID-19 By a Vector Based Vaccine Sputnik V in Patients with Chronic Myeloid Leukemia
  19. 21519
    “…Chart review identified patients who had received COVID-19 vaccines and had post-vaccination antibody titers drawn by July 2021 as part of routine care (n=63). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Incidence and Predictors of Sars-Cov-2 Antibody Responses Following COVID-19 Vaccination in Allogeneic Stem Cell Transplant Recipients
  20. 21520
    “…Yet only 6.6% (1/15) in this subgroup tested negative. Titer levels in seropositive patients ranged between 60 and 80,000 AU/ml (median: 5319). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Humoral Serologic Response to the BNT162b2 Vaccine Afterallogeneic Haematopoietic Cell Transplantation
Herramientas de búsqueda: RSS